Hikma and Rakuten Medical sign exclusive licensing agreement for AlluminoxTM platform cancer treatment for the Middle East and North Africa

Health and Beauty1
By:
On:

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive licensing and commercialisation agreement with Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercialising precision, cell targeting therapies based on its proprietary Alluminox™ platform. Under the terms of the agreement, Hikma hasContinue Reading